1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Kerala Ayurveda Limited

Kerala Ayurveda Limited

BBSE:KERALAYUR
139.75
INR
-1.70
(-1.20%)
-22.54EPS
2.40BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
33.02
36.97
43.53
47.76
55.77
58.63
72.17
58.36
75.79
88.15
94.22
99.04
107.6
115.73
Basic EPS, GAAP
0.7
2.23
2.56
2.9
2.66
2.32
3.69
-4.57
2.24
-0.85
-0.51
-11.6
-13.53
-22.62
Free Cash Flow per Basic Share
-1.31
-0.21
2.14
2.98
-9.6
11.64
1.56
6.02
-3.17
3.48
-1.88
-4.88
-24.65
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-9.74
-8.44
4.86
6.6
7.49
3.53
7.51
3.22
5.79
-8.35
15.5
-11.1
8.56
- -
Tangible Book Value per Share
-19.75
-18.38
-5.01
-3.61
-2.59
-6.49
-2.88
-7.1
-15.43
-23.2
2.91
-24.2
-4.62
- -
Basic Weighted Avg Shares
11
11
11
11
11
11
11
11
11
11
11
12
12
12
Sales/Revenue/Turnover
349
390
459
504
589
619
762
619
800
930
1,028
1,192
1,299
1,357
Operating Margin (%)
6.79
12.21
11.2
11.1
12.2
6.27
9.35
7.07
12.33
5.38
6.22
-7.18
-16.69
-17.02
Depreciation Expense
10
11
19
18
18
10
11
13
12
11
21
50
55
57
Net Income, GAAP
7
24
27
31
28
24
39
-48
24
-9
-6
-140
-163
-265
Effective Tax Rate (%)
47.4
20.77
33.38
21.54
30.89
18.55
10.67
- -
14.66
- -
185.44
- -
- -
- -
Profit Margin (%)
2.13
6.04
5.88
6.07
4.77
3.95
5.12
-7.83
2.95
-0.97
-0.54
-11.71
-12.57
-19.54
Working Capital
-132
-116
-278
-264
-34
7
24
17
-232
-375
-282
-472
-525
- -
LT Debt
517
537
191
202
428
494
524
585
372
424
219
222
180
- -
Total Equity
-92
-77
64
85
95
54
97
52
79
-68
213
-100
149
- -
Return on Invested Capital (%)
1.66
4.24
4.42
5.25
6.62
5.55
9.01
- -
11.33
- -
-6.31
- -
- -
- -
Return on Capital (%)
1.93
5.88
5.71
6
5.38
5.73
7.28
- -
9.83
- -
-6.16
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
50.56
37.77
42.04
66.9
-85.51
49.64
- -
- -
- -
- -
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
685
- -
LT Borrowings
- -
146
- -
LT Finance Leases
- -
34
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
13
13
Market Capitalization
3,808
2,050
2,403

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
469
- -
Cash, Cash Equivalents & STI
- -
80
- -
Accounts Receivable, Net
- -
138
- -
Inventories
- -
151
- -
Total Current Liabilities
- -
994
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
685
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-90.66%
-188.37%
-249.48%
Free Cash Flow
-32.7%
14.93%
406.96%
Net Income, GAAP
191.13%
416.81%
16.95%
Sales/Revenue/Turnover
11.69%
16.2%
8.98%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
275
304
311
313
1,192
2026
286
348
330
347
1,299
2027
332
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.33
3.1
-2.4
-12.78
-11.6
2026
1.92
-7.23
-3.69
-5.83
-13.53
2027
-6.24
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Vivek Sunder
Full Time Employees
414
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Athani Post Bangalore KL India 683 585
IPO Date
Feb 22, 1995
Website
keralaayurveda.biz
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Kerala Ayurveda Limited manufactures and markets authentic Ayurvedic products and provides holistic wellness solutions including clinics, academies, hospitals and Ayurvedic resorts; its core offerings encompass pain relief and joint care such as Myaxyl Cream, Myaxyl Pain Relief Oil, Sahacharadi Thailam and Yogaraja Guggulu Tablets; diabetic care including Glymin Tablets and Nisakathakadi Kwath; heart health with Liposem Tablets and Normact Tablets; gut health and digestion aids like Triphala Tablets, Avipathi Choornam and Dasamoolarishta; skin and hair care featuring Kumkumadi Thailam, Neelibringadi Keram, Nalpamaradi Keram and Winsoria Oil; immunity boosters such as Indukantham Kwath Tablets; stress management and cognitive support with Brahmi Pearls Capsules and Manasamithra Vatakam Gulika; women's health products including Menovin Tablets and Asokarishta; men's health formulations like Ajax Capsules; respiratory care such as Tuss Nil Cough Syrup and Histantin Tablets; along with oils, arishtas, kwaths, choornams, lehyams, ghrithams and tablets for liver health, kidney care, eye care, weight management and children's wellness. Founded in 1945 by Vaidyan K G K Panicker and headquartered in Aluva, Kochi, Kerala, India, the company operates primarily in India with international presence through subsidiaries in the United States, Germany and Singapore, targeting consumers seeking natural remedies for chronic conditions, general wellness and specialized Ayurvedic treatments. Recent developments include approval for issuance of shares worth up to 218.3 million rupees in November 2023 and plans to consider preferential allotment of shares as of December 2024; earlier in July 2023 it entered a business transfer agreement to acquire the Nutraveda nutraceutical product range; and in May 2023 it issued shares worth 72.8 million rupees to support expansion.